SG 233
Alternative Names: SG-233Latest Information Update: 17 Oct 2023
At a glance
- Originator Sana Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 12 Oct 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in USA (Parenteral) prior to October 2023 (Sana Biotechnology pipeline, October 2023)
- 12 Oct 2023 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (Parenteral) prior to October 2023 (Sana Biotechnology pipeline, October 2023)
- 12 Oct 2023 Discontinued - Preclinical for Precursor cell lymphoblastic leukaemia-lymphoma in USA (Parenteral) prior to October 2023 (Sana Biotechnology pipeline, October 2023)